近20年色素性视网膜炎基因治疗现状的文献计量学分析  

Bibliometric analysis of gene therapy for retinitis pigmentosa in recent 20 years

作　　者：施晓萌 张宇 刘艳[1] 骆世平 雷博 Shi Xiaomeng;Zhang Yu;Liu Yan;Luo Shiping;Lei Bo(Henan Provincial People’s Hospital,Henan Eye Hospital,Zhengzhou 450003,China;Eye Institute,Henan Academy of Medical Science,Zhengzhou 451163,China)

机构地区：[1]河南省人民医院河南省立眼科医院,郑州450003 [2]河南省医学科学院眼科研究所,郑州451163

出　　处：《中华眼底病杂志》2025年第3期221-230,共10页Chinese Journal of Ocular Fundus Diseases

基　　金：国家自然科学基金(82271084)。

摘　　要：目的了解2005年至2024年色素性视网膜炎(RP)基因治疗领域研究热点。方法以美国科学情报研究所Web of Science核心数据集为数据源,检索RP基因治疗相关文献。检索时间为2005年1月1日至2024年9月15日。采用R软件的bibliometrix软件包对发文量年变化趋势、文献被引频次、文献国家/地区分布、载文期刊分布进行分析;采用CiteSpace软件对关键词进行聚类分析和突现词分析。结果共纳入209篇RP基因治疗相关文献。该领域2005年至2024年年发文量整体呈波动上升趋势,其中2023年发文量最多,为26篇(12.4%,26/209);2006年发文量最少,为2篇(0.9%,2/209)。相关文献引用频次整体呈增长趋势。来自美国的通信作者总发文量最多,为98篇(46.9%,98/209)。作者发文量中,美国佛罗里达大学Hauswirth最多,为25篇(12.0%,25/209);机构发文量中,美国哥伦比亚大学最多,为55篇(26.3%,55/209)。期刊发文量中,Mol Ther最多,为25篇(12.0%,25/209);且该期刊2023年影响因子最高,为12.1。关键词聚类分析共获得8个有效聚类,分别是#0 P23H、#1 AAV、#2 PDE6B、#3 CRB1、#4 RPGR、#5 antisense oligonucleotide、#6 NR2E3、#7 NRL,各聚类相互交叉,延续性较好。突现词分析显示,突现时间最长是RNAi,其次是PDE、PDE6。USH2A、CRB1、CRISPR Cas9、base editing、ORF15为近年突现的关键词,并一直持续至今。结论2005年至2024年RP基因治疗研究文献呈增长趋势,其中美国研究机构和学者发文量最多。RHO、PDE6B、CRB1、RPGR、NR2E3、NRL基因研究较多,近年USH2A、CRB1基因和RPGR ORF15区域的研究逐渐增多。CRISPR Cas9和碱基编辑基因治疗策略也正在发展。ObjectiveTo investigate the current status of research in gene therapy for retinitis pigmentosa(RP)from 2005 to 2024.MethodsThe literature related to gene therapy for RP included in the Web of Science Core Collection dataset from January 1,2005 to September 15,2024 was retrieved and screened.The bibliometrix package of R software was used to analyze the annual trend of the number of publications,citation frequency,distribution of countries/regions of the literature,and distribution of journals containing the articles.CiteSpace software was used to perform keyword clustering analysis and the keywords bursts analysis.ResultsA total of 209 articles were included.There was an overall fluctuating upward trend of annual publications from 2005 to 2024,with the highest number of publications in 2023 at 26(12.4%,26/209),and the lowest number of publications in 2006 at 2(0.9%,2/209).There was an overall increasing trend in the frequency of citations to relevant literature.Corresponding authors from the United States had the highest total number of publications with 98(46.9%,98/209).Among authors,Hauswirth from the University of Florida,USA,had the most with 25(12.0%,25/209).Among institutions,Columbia University,USA,had the most with 55(26.3%,55/209).Among journals,Mol Ther had the most with 25(12.0%,25/209),and it had the highest 2023 impact factor of 12.1.Keyword clustering analysis yielded eight valid clusters,namely#0 P23H,#1 AAV,#2 PDE6B,#3 CRB1,#4 RPGR,#5 antisense oligonucleotide,#6 NR2E3,and#7 NRL,which intersected with each other with good continuity.The keywords bursts analysis showed that the keyword with the longest emergence time was RNAi,followed by PDE and PDE6.USH2A,CRB1,CRISPR Cas9,base editing,and ORF15 were keywords that emerged in recent years and were continuously studied.ConclusionsRP gene therapy research literature has shown an increasing trend from 2005 to 2024,with the highest number of publications from research organizations and scholars in the United States.Currently,studies focus on RHO,PDE6B,

关 键 词：色素性视网膜炎 基因治疗 热点分析 文献计量学 

分 类 号：R73[医药卫生—肿瘤]